Chapter 1

[1]        House of Representatives Votes and Proceedings, No. 27, 1 December 2016, p. 433.

[2]        The Hon. Sussan Ley MP, Minister for Health, House of Representatives Hansard, 1 December 2016, p. 5113.

[3]        Department of Health, Submission 22, p. 4.

[4]        Department of Health, Submission 22, p. 5.

[5]        Submissions and public hearing transcripts are available on the committee's website: https://www.aph.gov.au/senate/Community_Affairs/TGA2016MeasuresNo1.

[6]        Senate Standing Committee for the Scrutiny of Bills, Scrutiny Digest 1 of 2017, pp. 32‑34.

[7]        Senate Standing Committee for the Scrutiny of Bills, Scrutiny Digest 1 of 2017, pp. 34‑35.

[8]        Senate Standing Committee for the Scrutiny of Bills, Scrutiny Digest 1 of 2017, p. 35.

[9]        Senate Standing Committee for the Scrutiny of Bills, Scrutiny Digest 1 of 2017, pp. 35‑36.

[10]      Senate Standing Committee for the Scrutiny of Bills, Scrutiny Digest 1 of 2017, pp. 37‑38.

[11]      Senate Standing Committee for the Scrutiny of Bills, Scrutiny Digest 1 of 2017, pp. 38‑39.

[12]      Senate Standing Committee for the Scrutiny of Bills, Scrutiny Digest 3 of 2017, pp. 105, 110, 112, 114, 117 and 123.

[13]      Senate Standing Committee for the Scrutiny of Bills, Scrutiny Digest 3 of 2017, pp. 110, 113, 117 and 121.

[14]      Parliamentary Joint Committee on Human Rights, Human Rights Scrutiny Report, Report 2 of 2017, 21 March 2017, pp. 27‑28.

[15]      Parliamentary Joint Committee on Human Rights, Human Rights Scrutiny Report, Report 2 of 2017, 21 March 2017, p. 27.

[16]      Parliamentary Joint Committee on Human Rights, Human Rights Scrutiny Report, Report 2 of 2017, 21 March 2017, p. 28.

[17]      Senate Standing Committees on Community Affairs, Availability of new, innovative and specialist cancer drugs in Australia, 17 September 2015, https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/Cancer_Drugs/Report (accessed 22 March 2017).

[18]      Senate Standing Committees on Community Affairs, Availability of new, innovative and specialist cancer drugs in Australia, 17 September 2015, p. xi.

Chapter 2 - Issues

[1]        Melanoma Patients Australia, Submission 5; ACON, Submission 10; Australian Federation of AIDS Organisations and the National Association of People with HIV Australia, submission 15; Haemophilia Foundation of Australia, Submission 19; Rare Cancers Australia, Submission 25; and Consumers Health Forum, Submission 27.

[2]        AusBiotech, Submission 3; Roche Products, Submission 4; IVD Australia, Submission7; Medical Technology Association of Australia, Submission 8; Novartis, Submission 9; Complementary Medicines Australia, Submission 11; Biotronik Australia Pty Ltd, Submission 12; Pfizer Australia, Submission 14; Merck Sharp and Dohme, Submission 18; Australian Medical Device Manufacturers and Distributers, Submission 20; Medicines Australia, Submission 21; Swisse Wellness, Submission 23; Stryker, Submission 24; Cancer Drugs Alliance, Submission 26; Medtronic Australasia Pty Ltd, Submission 28; Bristol-Myers Squibb Australia, Submission 29; Australian Self Medication Industry, Submission 30; Generic and Biosimilar Medicines Association Australia, Submission 34; Glaxo Smith Klein, Submission 35; Johnson and Johnson Pty Ltd, Submission 37; and Cochlear Ltd, Submission 42.

[3]        Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Submission 1; Australasian Tuberculosis Forum, Submission 2; Pharmaceutical Society of Australia, Submission 6; and Day Hospitals Australia, Submission 13.

[4]        ANSTO, Submission 33; and Prostheses List Advisory Committee, Submission 16.

[5]        Senate Standing Committee for the Selection of Bills, Report, No. 1 of 2017, Appendix 5.

[6]        Adjunct Professor John Skerritt, Deputy Secretary, Department of Health, Committee Hansard, 17 March 2017, p. 24.

[7]        Johnson and Johnson Pty Ltd, Submission 37, p. 5. See also, for example, Ms Elizabeth de Somer, Director Policy and Research, Medicines Australia, Committee Hansard, 17 March 2017, p. 12.

[8]        Department of Health, Submission 22, p. 7.

[9]        Department of Health, Submission 22, p. 8.

[10]      Department of Health, Submission 22, p. 8.

[11]      Department of Health, Submission 22, p. 9.

[12]      Department of Health, Submission 22, p. 9.

[13]      Department of Health, Submission 22, p. 10.

[14]      Senate Standing Committee for the Scrutiny of Bills, Scrutiny Digest 1 of 2017, pp. 34–35.

[15]      Australian Dental Industry Association, Submission 44, p.18.

[16]      Australian Dental Industry Association, Submission 44, p.18.

[17]      AusBiotech, Submission 3, [p. 2].

[18]      Haemophilia Foundation of Australia, Submission 19, p. 2.

[19]      Royal Australasian College of Physicians, Submission 43, p. 1.

[20]      Royal Australasian College of Physicians, Submission 43.1, p. 3.

[21]      Ms Josephine Root, Policy Manager, Consumers Health Forum, Committee Hansard, 17 March 2017, p. 6.

[22]      Ms Josephine Root, Policy Manager, Consumers Health Forum, Committee Hansard, 17 March 2017, p. 6.

[23]      Mr George Faithfull, Medical Technology Association of Australia, Committee Hansard, 17 March 2017, p.16.

[24]      Ms Elizabeth de Somer, Director Policy and Research, Medicines Australia, Committee Hansard, 17 March 2017, p. 10.

[25]      Ms Josephine Root, Policy Manager, Consumers Health Forum, Committee Hansard, 17 March 2017, p. 8.

[26]      Adjunct Professor John Skerritt, Deputy Secretary, Department of Health, Committee Hansard, Friday 17 March 2017, p. 26.

[27]      Adjunct Professor John Skerritt, Deputy Secretary, Department of Health, Committee Hansard, 17 March 2017, p. 33.

[28]      Day Hospitals Australia Ltd, Submission 13, p.1.

[29]      See for example, the Medical Technology Association of Australia, Submission 8, and IVD Australia, Submission 7.

[30]      Professor Terry Campbell, Chair, Prostheses List Advisory Committee, Submission 16, p. 2.

[31]      Adjunct Professor John Skerritt, Deputy Secretary, Department of Health, Committee Hansard, 17 March 2017, p. 21.

[32]      Royal Australasian College of Physicians, Submission 43, p. 1.

[33]      Ms Josephine Root, Policy Manager, Consumers Health Forum, Committee Hansard, 17 March 2017, p. 7.

[34]      Adjunct Professor John Skerritt, Deputy Secretary, Department of Health, Committee Hansard, 17 March 2017, p. 20.

[35]      Adjunct Professor John Skerritt, Deputy Secretary, Department of Health, Committee Hansard, 17 March 2017, p. 20.

[36]      Ms Josephine Root, Policy Manager, Consumers Health Forum, Committee Hansard, 17 March 2017, p. 8.

[37]      Mr George Faithfull, Medical Technology Association of Australia, Committee Hansard, 17 March 2017, p.16.

[38]      IVD Australia, Submission 7, p. 5.

[39]      Medical Technology Association of Australia, Submission 8, p. 3.

[40]      Adjunct Professor John Skerritt, Deputy Secretary, Department of Health, Committee Hansard, 17 March 2017, p. 30.

Labor Senators' Additional Comments

[1]        Submission 22, p. 6.

[2]        Submission 27, p. 5.